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EvidEncE-basEd answEr
A
	 Do	complementary	agents	
lower	HbA1c	when	used	with	
standard	type	2	diabetes	therapy?
	 No, there is no high-quality 
 evidence	 that	 supports	 using	
complementary	 or	 alternative	 agents	 to	
lower	hemoglobin	A1c	(HbA1c)	in	patients	
with	 noninsulin-dependent	 type	 2	 diabe-
tes.	Oral	chromium	in	widely	varying	doses	
reduces	HbA1c	a	small	amount	(strength	of	
recommendation	 [SOR]:	C, meta-analysis	
of	 low-quality	 randomized,	 controlled	 tri-
als	 [RCTs]	 of	 disease-oriented	 outcomes,	
with	inconsistent	results).	
Oral	 cinnamon	 1	 to	 3	 g/d	 causes	 a	
small	 (<0.1%)	 drop	 in	 HbA1c	 (SOR:	 C,	
meta-analysis	 of	 low-quality	 RCTs	 of	 dis-
ease-oriented	outcomes).	
Fenugreek,	milk	 thistle,	 safflower	 oil,	
and	sweet	potato	extract	may	also	 reduce	
HbA1c	(SOR:	C,	small,	low-quality	RCTs	of	
disease-oriented	outcomes).	
Evidence summary 
Almost	 all	 complementary	 and	 alternative	
agents	reviewed	here	were	tested	against	pla-
cebo,	 and	 most	 were	 used	 in	 combination	
with	 standard	 therapy,	 usually	 identified	 as	
diet	with	or	without	oral	hypoglycemic	agents	
(tABLE).1-8
Meta-analyses evaluate effects  
of chromium and cinnamon
A	 meta-analysis	 of	 13	 RCTs	 evaluating	 the	
effect	 of	 oral	 chromium	 in	 patients	 with	
type	 2	 diabetes	 (age	 range	 not	 given)	 found	
a	 small	 improvement	 in	HbA1c.1	 Limitations	
of	 the	 meta-analysis	 included	 a	 wide	 range	
of	 chromium	 dosages	 and	 preparations.	 Ten	
studies	showed	no	benefit,	and	of	the	3	show-
ing	 improvement,	 the	 researchers	 rated	 2	 as	
poor-quality.
A	meta-analysis	of	5	RCTs	assessing	 the	
effect	of	oral	cinnamon	in	patients	with	type	
2	diabetes,	 42	 to	 71	 years	of	 age,	 found	 that	
cinnamon	 produced	 a	 clinically	 irrelevant	
but	statistically	significant	decrease	in	mean	
HbA1c.2	After	 analyzing	 the	 2	RCTs	with	 the	
largest	effects,	the	researchers	concluded	that	
cinnamon	might	have	a	greater	effect	 in	pa-
tients	with	poorly	controlled	diabetes	(base-
line	HbA1c>8.2%).	
When	 they	 evaluated	 these	 RCTs	 for	
study	 homogeneity,	 they	 found	 significant	
differences	 among	 the	 studies	 in	 subject	
age,	gender,	ethnicity,	body	mass	index,	dis-
ease	 duration,	 concurrent	medications,	 and	
baseline	 HbA1c	 levels,	 as	 well	 as	 variations	
in	cinnamon	dose,	preparation,	and	therapy	
duration.	Furthermore,	only	one	of	the	stud-
ies	 reported	 randomization	 methods	 and	
whether	allocation	was	concealed.
What about caiapo, fenugreek,  
milk thistle, and safflower oil?
Two	small,	moderate-quality	RCTs	of	caiapo	
(sweet	potato	skin	extract)	in	diet-controlled	
patients	 with	 diabetes	 demonstrated	 small	
but	 possibly	 clinically	 significant	 reductions	
in	HbA1c	between	the	intervention	and	con-
trol	groups.3,4	
Four	 small,	 placebo-controlled	 RCTs	
of	 fenugreek,	 milk	 thistle,	 and	 safflower	 oil	
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found	 statistically	 and	 clinically	 significant	
reductions	 in	 HbA1c,	 but	 all	 these	 studies	
were	of	poor	quality	with	unclear	methods	of	
randomization,	threats	to	blinding,	and	a	lack	
of	baseline	demographics.5-8	
Recommendations 
Both	 the	 American	 Diabetes	 Association	
(ADA)	and	the	Diabetes	UK	Nutrition	Work-
ing	 Group	 state	 that,	 “there	 is	 no	 clear	 evi-
dence	 of	 benefit	 from	 vitamin	 or	 mineral	
supplementation	 in	 people	 with	 diabetes	
(compared	 with	 the	 general	 population),	
who	do	not	have	underlying	deficiencies.”9,10	
The	 ADA	 specifically	 states	 that	 chromium	
cannot	be	recommended	because	it	lacks	any	
clear	benefit.9			 	 	 																JFP
tABLE
Effect	of	complementary	or	alternative	agents	on	HbA1c	in	type	2	diabetes
caa* Dose/
day
concurrent  
diabetes  
therapy
Study  
type
Study 
size
Study  
duration
Difference in hba1c 
(in hba1c units) 
95% cI or P 
value
chromium1 1.28-
1000 
mcg
Not given meta-
analysis of 
13 rcTs
381 3 wk-8 mo -0.6† -0.9 to -0.2
cinnamon2 1-3 g Various oral 
hypoglycemic 
agents‡
meta-
analysis of 
5 rcTs
315 1.5-4 mo -0.09 (WmD)† -0.14 to -0.04
caiapo3 4 g Diet only rcT 61 5 mo -0.21 (caiapo)§ P=.08
+0.25 (placebo)§ P=.0001
caiapo4 4 g Diet only rcT 61 3 mo -0.53 (caiapo)§ P<.001
+0.06 (placebo)§ P=.23
Trigonella  
foenum-graecum 
(fenugreek)5
6.84 g Sulfonylurea rcT 69 3 mo -1.46 (fenugreek)§ P<.05
-0.41 (placebo)§ P<.05
Silybum marianum 
(milk thistle)6
200 mg metformin and 
sulfonylurea
rcT 51 4 mo -1.0 (milk thistle )§ P<.001
+1.2 (placebo)§ P<.0001
Silybum marianum 
(milk thistle)7
200 mg Sulfonylurea rcT 38 4 mo -1.5 (milk thistle )§ P<.05
-0.5 (placebo)§ P=NS
Safflower oil vs 
conjugated linoleic 
acid8
8 g Various oral 
hypoglycemic 
agents‡
DBrcD 35 4 mo -0.6 (safflower oil)§ P=.0007
+0.1 (conjugated 
linoleic acid)§ 
P=NS
caa, complementary or alternative agents; cI, confidence interval; DBrcD, double-blind, randomized, crossover design; hba1c, glycosylated hemoglobin 
a1c; NS, not significant; rcT, randomized controlled trial; WmD, weighted mean difference.
*all caas were compared against placebo, with the exception of safflower oil, which was compared against conjugated linoleic acid supplementation. 
† change in hba1c means at study endpoint; the difference in hba1c in intervention vs placebo groups.
‡ oral hypoglycemic agents included a-glucosidase inhibitors, biguanides, glinides, glitazones, sulfonylureas, and thiazolidinediones.
§ change in hba1c means at study endpoint; the change in hba1c from baseline.
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For information on pain management, go to our Web site at  
www.currentpainperspectives.com and check out these articles:
n Diagnosing fibromyalgia and myofascial pain syndrome: A guide
n Neurogenic thoracic outlet syndrome: Often overlooked, but treatable
n How best to prevent acute pain from becoming chronic?
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